,
Crestone Pharma

Coming – January 21

Meet The Founder: A Groundbreaking Treatment For Autism

Date and Time

January 21

–

8:30 – 10:30 AM MT

Details will be provided upon RSVP approval

About this Event

Please join us in Boulder for an exclusive breakfast meeting with Nebojsa Janjic, Ph.D., CEO and President of Crestone Pharma, a Colorado-based biotechnology company that is developing highly targeted antibiotics that have the potential to reduce the core symptoms of Autism, as well as several other indications.

Autism affects millions of children and families worldwide, yet there are no approved treatments that address its core biological causes. Emerging science shows that gut-derived metabolites—particularly p-cresol—can disrupt brain chemistry and development. Crestone is advancing CRS3123, a first-in-class, precision antibiotic that targets only the bacteria responsible for producing p-cresol. By restoring microbiome balance, this approach aims not just to manage symptoms, but to intervene at the biological root cause of autism.

Register today to join us in Boulder to hear more about Crestone and their entire pipeline of precision antibiotics. For families who care deeply about creating lasting impact, Crestone offers the rare opportunity to align capital with compassion and scientific innovation. 

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.